ReviewCureus2026
Efficacy and Safety of Hopantenic Acid in Pediatric Neurological and Developmental Disorders: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodevelopmental disorders (NDDs) are pediatric conditions characterized by impairments in cognition, behavior, language, motor coordination, and social functioning. Hopantenic acid (N-pantoyl-γ-aminobutyric acid {GABA}), a selective partial GABA-B receptor agonist with neuroprotective and nootropic properties, has been utilized in various pediatric neurological disorders; however, consolidated evidence regarding its efficacy and safety remains limited. This systematic review and meta-analysis aimed to evaluate the therapeutic efficacy and safety of hopantenic acid in pediatric NDDs and to assess its impact across major neurodevelopmental domains represented by the language, cognition, motor coordination, and social communication (LCMS) framework. The review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Electronic databases, including PubMed/MEDLINE, SpringerLink, ScienceDirect, and regional neurological journals, were systematically searched for controlled clinical trials involving children and adolescents treated with hopantenic acid. Quantitative synthesis was performed using a random-effects Mantel-Haenszel model to calculate pooled risk ratios (RR) with 95% confidence intervals (CI), while outcomes unsuitable for pooling were synthesized narratively. Six controlled studies involving 439 pediatric participants were included, of which four studies (n=272) were eligible for meta-analysis. Pooled analysis demonstrated greater clinical improvement with hopantenic acid compared with control therapy (RR=2.13, 95% CI: 1.11-4.08; I²=81%; p=0.02). More pronounced effects were observed in epilepsy and anxiety-related conditions, while moderate benefits were reported in hypoxic-ischemic encephalopathy. Narrative synthesis further indicated improvements across LCMS-related domains, including speech and hearing development, attention, memory, psychomotor performance, behavioral regulation, visual-motor coordination, social functioning, emotional stability, learning ability, and overall quality of life, without increasing seizure frequency. Safety outcomes were favorable, with adverse events comparable to placebo and no treatment-related serious adverse events reported. Overall, current evidence suggests that hopantenic acid may provide potential clinical and neurodevelopmental improvement across multiple pediatric NDDs, with benefits extending beyond symptomatic relief to broader developmental functioning. Its multimodal neuroprotective and GABA-B modulatory mechanisms provide a plausible biological basis for these findings. Nevertheless, inter-study heterogeneity and limited geographic representation highlight the need for larger, well-designed randomized controlled trials with standardized neurodevelopmental endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.